Physician profile
Laura E Wilson
NPI 1801830740
$1,983.43
in general payments reported to CMS, 2019-2025
30 companies · $246 in 2025
The $246 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $102 · 2021: $260 · 2022: $501 · 2023: $432 · 2024: $247 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $210.30 | 2019-2025 | Wegovy, Saxenda |
| Merck Sharp & Dohme LLC | $186.99 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Corium, LLC | $180.60 | 2022-2023 | Azstarys |
| Pfizer INC. | $178.92 | 2019-2024 | |
| Abbvie INC. | $144.92 | 2023-2024 | Vraylar |
| Exact Sciences Corporation | $93.79 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.02 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $84.57 | 2022 | |
| Sanofi Pasteur INC. | $83.77 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $83.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $77.95 | 2024-2025 | Voquezna |
| Tris Pharma INC | $77.93 | 2021-2025 | Dyanavel Xr |
| Antares Pharma, INC. | $75.89 | 2022-2025 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $61.35 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $47.45 | 2024-2025 | Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $38.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.56 | 2024-2025 | Airsupra |
| Amgen INC. | $29.16 | 2021 | |
| Esperion Therapeutics, INC. | $28.62 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $27.47 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2019-2022 | |
| Kaleo, INC. | $15.72 | 2021 | |
| Lilly USA, LLC | $15.69 | 2024 | Jardiance |
| Amarin Pharma, INC. | $14.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2020 | |
| Sobi, INC | $13.99 | 2019 | |
| Becton, Dickinson and Company | $13.74 | 2025 | Bd Onclarity |
| Ironwood Pharmaceuticals, INC | $13.57 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2024 | Zoryve |
| Organon LLC | $12.27 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.